BRD9 warrants further investigation in ERG fusion positive cancers and possibly co-targeted with ERG inhibition, as ERG depends on BAF complexes for its epithelial to mesenchymal transition (EMT) [72]. This evidence concerns the gene BRD9 and cancer.